OR WAIT null SECS
August 09, 2021
Article
ARX517 is being explored in patients with prostate cancer and other PSMA-expressing solid tumors.
August 05, 2021
Patient tumors must express PSMA as identified by 68Ga-PSMA-11 or 18F-DCFPyl PSMA PET/CT scanning.
July 28, 2021
The theranostic 64/67Cu SAR-bisPSMA combines the PSMA PET imaging product 64Cu-SAR-bisPSMA and the PSMA targeted therapy 67Cu-SAR-bisPSMA.
July 23, 2021
A recent analysis suggested that nomograms could predict outcomes with the PSMA-targeted agent Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.
July 13, 2021
“This is a completely new therapeutic concept; a precision medicine that delivers radiation directly to a high incidence tumor," said Ken Herrmann, MD.
Photodynamic diagnosis with blue light was associated with improved outcomes compared to white light cystoscopy in patients with bladder cancer who received TURBT.
July 12, 2021
With supporting data from larger series, using Ga-68 PSMA PET as a lymph node invasion prediction tool instead of nomograms could avoid unnecessary lymphadenectomies during radical prostatectomy,” said Yakup Kordan, MD.
July 11, 2021
“This confirms the potential of PSMA PET to distinguish between risk groups for MFS,” said Dr. Christoph Würnschimmel.
June 17, 2021
Piflufolastat F 18 effectively detected and pinpointed metastatic lesions with high positive predictive value, regardless of anatomic region.
June 16, 2021
The designation, which will expedite the development and review of 177Lu-PSMA-617 in this setting, is based on findings from the phase 3 VISION trial.
